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The chemokine (CK) receptor 5 (CCR5) is necessary for two
adjacent cysteines (CC)-CKs such as Regulated upon
Activation Normal T cell Expressed and Secreted, a/o
Macrophage Inflammatory Protein 1a/b to mediate their
inflammatory properties. The CCR5 gene polymorphism with
32-basepair deletion (d32) leads to receptor inactivation/
dysfunction in homo/heterozygous individuals. We have
evaluated its role in both initiation and/or progression of
primary immunoglobulin A (IgA) nephropathy (IGAN) in a
case–control study involving a prospective cohort of 318
IGAN patients and a matched group of 294 controls.
Genotyping was performed by a two-specific primers single
polymerase chain reaction technique: normal allele (nl) vs
d32 allele. The d32 allele frequency was not different in
patients (11.0%) vs controls (8.3%), indicating no significant
influence on IGAN initiation. Genotype to clinical phenotype
correlation demonstrated that progression to renal/patient
death was associated with the d32 allele: 18.2% (12 out of 66
with d32) vs 8.3% (21 out of 252); v2¼ 6.73; P¼ 0.017. The
Kaplan–Meier survival without renal/patient death was worse
in d32-positive patients (log-rank test; P¼ 0.002). The Cox
regression analyses confirmed that the nl/nl genotype was a
significant and independent protective factor for progression
to end-stage renal failure (ESRF)/dialysis: b/standard error
(s.e.)¼3.1; v2¼ 9.5; relative risk¼ 0.31 (95% confidence
interval 0.15–0.65); P¼ 0.002. The d32–CCR5 polymorphism
played a significant role in the progression of primary IGAN,
with the nl/nl genotype being an independent protective
factor for late progression towards ESRF/dialysis. These data
raise question about the usefulness of systematic CCR5
genotyping in IGAN patients.
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The name chemokine (CK) results from the contraction of
chemotactic cytokines.1 CKs are classified into four different
groups:2 CXC-CKs, CC-CKs, C-CKs and CX3C-CKs, de-
pending on their chemical structure with regard to the
position of the cysteine (C) residues.
The CC-CKs family1,2 is characterized by two adjacent
cysteines and includes the following molecules: Regulated
upon Activation Normal T cell Expressed and Secreted
(RANTES) monocyte chemoattractant protein 1–4, and
Macrophage Inflammatory Protein (MIP) 1a and 1b.
Globally, these small peptides have an inflammatory,
phlogistic role, with the attraction of different leucocytes,
mainly monocytes, T lymphocytes, and sometimes, in
addition, eosinophils/basophils, and others.
These CKs should bind CK receptors in order to mediate
their biological effects through G protein interaction. To each
class of CKs corresponds a class of receptors. For example,
the CC-CKs have to bind to CC receptors, which are
classified from 1 to 10. We focus our interest on the CC-CK
receptor 5 (CCR5),3,4 which is specific for the CC-CKs
family, but not for one molecule, because it can bind
RANTES or MIP 1a or 1b. CCR5 is a seven-transmembrane-
domain receptor expressed constitutively on monocytes/
macrophages and on lymphocytes. So it plays a major role
in leucocytes trafficking. Pathologically, the intracellular
penetration of human immunodeficiency virus-1 in CD4þ
T lymphocyte is mediated by CCR5.5
A functional polymorphism for CCR5 has been de-
scribed:6–8 it consists of a 32-basepair deletion (d32) in the
open reading frame, present in about 1% of the Caucasian
normal population as a homozygous defect and in about 10%
for the mutant allele frequency. Individuals with this
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homozygous deletion (d32/d32) have been found to be
resistant to human immunodeficiency virus-1 (HIV-1)
infection despite regular exposure.6–8 In fact, this mutation
leads to the inactivation of the CCR5 protein, which is a
necessary coreceptor for HIV intracellular penetration.5
The CCR5 has been involved in different types of renal
inflammation9,10 both in glomerulonephritis11 and in renal-
transplant rejection.12 At the initiation phase, all types of
intrinsic renal cells are able to secrete CKs in response to
immunologic, toxic, ischemic or mechanic injuries. This will
lead to persistent leucocyte infiltration and activation,
especially in the interstitium, resulting in fibrosis with
progression of the lesions. More precisely, in humans,
CCR5-positive T lymphocytes were identified among inter-
stitial focal infiltrates in transplant rejection,12 in interstitial
nephritis, and in different types of chronic glomerulo-
nephritis, including immunoglobulin A (IgA) nephropathy
(IGAN).11 IGAN is the most frequent type of chronic
glomerulonephritis13 worldwide.
All these data led us to study the influence of this CCR5
polymorphism on both the initiation/occurrence and the
progression of the disease in our well-characterized prospec-
tive Saint-Etriune Cohort (STET-CO) of IGAN patients.
RESULTS
Genotypes and alleles distributions of CCR5 polymorphism
in IGAN- STET-CO vs Controls
The genotypes distribution demonstrated a mild borderline
excess of patients with d32 allele (heterozygousþ
homozygous): 66 out of 318 (20.8%) vs 44 out of 294
(15.0%) in controls: w2¼ 3.47; Fisher’s exact test; P¼ 0.07
(Table 1). However, the alleles frequencies were not
significantly different.
So, the d32–CCR5 polymorphism played no significant
role in occurrence/initiation of the disease.
Genotypes and alleles distributions of CCR5 polymorphism
according to the final clinical outcome of the patients
These patients fall into three subgroups: nonprogressors
(N¼ 240), progressors (towards chronic renal failure (CRF);
N¼ 47) and major progressors (towards end-stage renal
failure (ESRF)/dialysis; N¼ 31) (Table 2).
The data showed a significant difference for both
genotypes and alleles distributions among the three sub-
groups. In fact, there was a significant concentrating effect
in the major progressors subgroup, with d32 allele frequency
reaching 22.6 vs 9.8% in patients with no progression
(Pc¼ 0.01) and vs 8.3% in controls (Fisher exact P-value¼
0.001). So, there was clearly an association between d32 allele
and major progression.
Progression of IGAN-STET-CO patients according to
genotypes (genotype to clinical phenotype correlation)
The number of homozygous patients was very low (four of
318) (1.3%), but in accordance with the allelic frequency in
the Caucasian population. These four patients were two
males and two females, and two reached ESRF with dialysis
(one female, one male), while two kept normal renal
function.
So, for all the remaining study, we split the patients into
two subgroups according to genotypes: normal allele (nl/nl)
(N¼ 252) vs with d32 allele (heterozygousþ homozygous;
N¼ 66) for the different comparisons.
At the time of diagnosis, there were no significant
differences between the two subgroups ‘nl/nl’ vs ‘with d32
allele’ (Table 3), especially for the classical independent risk
factors for progression: age at onset, Global Optical Score
(GOS)1, 24 h proteinuria, and hypertension (HT). However
the percentage of patients with overweight/obesity was greater
for the d32 allele subgroup (50.0 vs 37.7%; w2¼ 3.29; P¼ 0.09),
but remained of borderline significance. Nevertheless, mean
body mass index (BMI) values were not different.
Table 1 | Genotypes and alleles distribution of CCR5 poly-
morphism in IGAN-STET-CO vs Controls
Controls IGAN
N (%) N (%) v2 P
Genotypes
nl/nl 250 (85.0) 252 (79.2)gnl/d32 39 (13.3) 62 (19.5) 4.42 NS (0.11)
d32/d32 5 (1.7) 4 (1.3)
N 294 (100) 318 (100)
Alleles
nl 539 (91.7) 566 (89.0)
d32 49 (8.3) 70 (11.0) 2.49 NS (0.12)
N 588 (100) 636 (100)
Genotypes
nl/nl 250 (85.0) 252 (79.2)
With d32 44 (15.0) 66 (20.8) 3.47 NS (0.06)
N 294 (100) 318 (100) Fisher exact test=0.07
N¼ Total.
Table 2 | Genotypes and alleles distributions according to the
final clinical outcome (GFR stages after Cockcroft formula)
Progression GFR
No
(stages 1/2)
Yes
(stages 3/4)
Major
(stage 5) v2 P
Genotypes
nl/nl 195 (81.3) 38 (80.9) 19 (61.3)gd32/nl 43 (17.9) 9 (19.1) 10 (32.3) 11.88 0.02
d32/d32 2 (0.8) 0 (0.0) 2 (6.4)
Total 240 (100.0) 47 (100.0) 31 (100.0)
Alleles
nl/nl 433 (90.2) 85 (90.4) 48 (77.4) 9.40 0.01
d32 47 (9.8) 9 (9.6) 14 (22.6) (Major vs
No: Pc=0.01)
Total 480 (100.0) 94 (100.0) 62 (100.0)
Genotypes
nl/nl 195 (81.3) 38 (80.9) 19 (61.3)
with d32 45 (18.7) 9 (19.1) 12 (38.7) 6.74 0.004
Total 240 (100.0) 47 (100.0) 31 (100.0)
FU time
Median (months) 123 138 144 NS
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At last follow-up (FU) (Table 4), the mean plasma
creatinine was greater for the subgroup ‘with d32 allele’:
respectively, 224.9 (276.8) vs 156.7 (191.9) mmol/l; t¼2.33;
P¼ 0.02; the percentage of patients with CRF was 31.8 vs
22.6% (w2¼ 2.39; P¼NS), but the distribution of glomerular
filtration rate (GFR) stages was significantly worse (w2¼ 9.34;
P¼ 0.05). The percentage of patients reaching the primary
event (renal death or patient death) was 18.2% (12 out of 66)
for ‘d32 allele’ vs 8.3% (21 out of 252); w2¼ 5.45; P¼ 0.02.
Comparisons between the patients reaching the primary
event (ESRF/death; N¼ 33) and the others (N¼ 285)
demonstrated only the following significant differences at
the time of diagnosis: an increased GOS: 11.6 vs 6.4
(t¼11.2; Po0.0001); more frequent proteinuria
(40.30 g/day): 100% (33 out of 33) vs 53% (150 out of
285) (w2¼ 27.2; Po0.0001) and more abundant proteinuria
(41 g/day): 82% (27 out of 33) vs 23% (66 out of 285)
(w2¼ 51.8; Po0.0001); more hypertensive patients: 82% (27
out of 33) vs 26% (75 out of 285) (w2¼ 41.8; Po0.0001);
more patients with already CRF: 73% (24 out of 33) vs 14%
(39 out of 285) (w2¼ 64.90; Po0.0001); and a greater
number of patients with overweight/obesity: 61% (20 out of
33) vs 38% (108 out of 285) (w2¼ 6.3; P¼ 0.01).
Among the 31 patients having reached ESRF/dialysis,
comparisons according to CCR polymorphism (19 nl/nl
patients vs 12 patients with d32) exhibited no differences
except for the following: the number of patients with significant
crescent (C) proliferation (X10% of glomeruli with crescents)
on first renal biopsy (RB1) was 8% (one out of 12; C¼ 21%)
for d32 vs 32% (six out of 19; C¼ 11, 16, 25, 43, 57, 71%) for
nl/nl (w2¼ 2.7; P¼ 0.13). In addition, no patient in the d32
subgroup vs four out of 19 (21%) in the nl/nl subgroup fulfilled
the definition criteria of endo/extracapillary glomerulonephritis
(X25% of glomeruli with crescents) (w2¼ 2.60; P¼ 0.10), but,
overall, only 20 out of 318 (6.3%) patients had significant
crescent proliferation (X10% of glomeruli with crescents) and
d32 patients were older at disease onset: 44.5 (16.7) years vs 36.9
(16.7) for nl/nl patients (t¼1.24; P¼NS).
The survival data according to Kaplan–Meier confirmed
the worse survival without renal/patient death (Figure 1) in
patients ‘with d32 allele’ as compared to nl/nl patients (log
rank test: w2¼ 9.67; P¼ 0.002). Divergence of the two curves
was evident after 10 years from disease onset. After exclusion
of all patients (N¼ 20) with significant crescent proliferation
on RB1 (e.g. exclusion of seven patients having reached the
primary end point), survival without renal/patient death was
significantly worse in patients with d32 allele (log rank test:
w2¼ 13.88; P¼ 0.0002).
By Cox univariate analysis, we have analyzed the influence
of all potential or known risk factors for progression to ESRF
Table 3 | Clinical and pathological characteristics at the time of diagnosis (RB1) and according to CCR5 genotypes (nl/nl vs with
d32 allele)
Parameters Whole group nl/nl genotype With d32 allele Test P
Number 318 252 66
Gender: male (%) 220 (69.2) 172 (68.3) 48 (72.7) w2=0.85 NS
Age at onset (years)
Mean (s.d.) 34.8 (15.0) 34.7 (15.2) 35.3 (14.3) t=0.28 NS
Median 34.0 33.6 35.5 U-test NS
At diagnosis (RB1)
Age at RB1 (years)
Mean (s.d.) 40.1 (14.7) 40.2 (14.7) 39.7 (14.9) t=0.25 NS
Median 40.2 40.2 39.9 U-test NS
Time (onset to RB1, months): mean (s.d.) 63.7 (94.0) 66.4 (98.7) 53.3 (73.2) t=1.005 NS
GOS1: mean (s.d.) 6.90 (3.01) 6.90 (2.95) 6.89 (3.28) t=0.006 NS
Proteinuria (g/day) stagesa
Absent (o0.30 g/day) (N (%)) 135 (43.5) 109 (44.3) 26 (40.6)g0.30–1.0 g/day (N (%)) 90 (29.0) 70 (28.5) 20 (31.3) w2=0.33 NS
41 g/day (N (%)) 85 (27.5) 67 (27.2) 18 (28.1)
Mean (s.d.) 1.50 (1.47) 1.46 (1.33) 1.66 (1.89) t=0.75 NS
BMI (kg/m2): mean (s.d.) 24.6 (4.2) 24.5 (4.2) 25.0 (4.1) t=0.85 NS
Overweight/obesity: (N (%)) 128 (40.3) 95 (37.7) 33 (50.0) w2=3.29 NS (0.09)
Hypertension: (N (%)) 102 (32.1) 80 (31.7) 22 (33.3) w2=0.06 NS
P creatinine (mmol/l): (mean (s.d.)) 123.8 (122.2) 121.7 (119.8) 131.53 (131.2) t=0.58 NS
GFR stages (N (%))
1 148 (46.5) 116 (46.0) 32 (48.5)g2 107 (33.6) 87 (34.5) 20 (30.3)3 42 (13.2) 31 (12.3) 11 (16.7) w2=2.54 P=NS4 13 (4.1) 12 (4.8) 1 (1.5)
5 8 (2.5) 6 (2.4) 2 (3.0)
CRF (o60 ml/min) (N (%)) 63 (19.8) 49 (19.4) 14 (21.2) w2=0.10 NS
ESRF/dialysis (N (%)) 8 (2.5) 6 (2.4) 2 (3.0) NS
aEight patients with ESRF were excluded from this analysis (N=310); mean proteinuria is given only for proteinuric patients.
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(Table 5). The most powerful factors were by order: 24-h
proteinuria/RB1, GOS1, absence of CRF/RB1, absence of HT/
RB1, age at disease onset and CCR5 polymorphism. For this
last factor, the genotype nl/nl was in fact significantly
protective for ESRF occurrence with a relative risk (RR) of
0.31 (95% confidence interval 0.15–0.65); P¼ 0.002. An
IGAN patient with nl/nl CCR5 genotype had an RR
reduction rate of 69% for the occurrence of ESRF event.
The absence of overweight/obesity and female gender were of
borderline significance (respectively, P¼ 0.06 and 0.07).
When all these significant covariates were analyzed by
forward stepwise Cox multifactorial regression, CCR5-nl/nl
genotype was sorted out in third position after GOS1 (b/
s.e.¼ þ 8.0; w2¼ 64.3; Po0.0001; RR¼ 1.45) and age at
onset (b/s.e.¼ þ 3.2; w2¼ 10.4; P¼ 0.002; RR¼ 1.05), with
the following characteristics: b/s.e.¼ þ 2.4; w2¼ 5.5;
P¼ 0.02; RR¼ 0.39). So, the nl/nl genotype remained an
independent and significant protective factor for progression
towards ESRF/dialysis.
The secondary end point of this study was the occurrence
of CRF. Kaplan–Meier survival curves without CRF (Figure 2)
and according to CCR5 polymorphism also demonstrated a
worse survival for patients with d32 allele (log rank test:
w2¼ 4.83; P¼ 0.03). Factors influencing survival without
CRF were analysed by Cox monovariate analysis (Table 6).
Table 4 | Clinical and pathological characteristics at the last follow-up and according to CCR5 genotypes (nl/nl vs with d32
allele)
Parameters Whole group nl/nl genotype With d32 allele Test P
Number 318 252 66
Exposure time (months) (onset to last FU/ESRF)
Mean (s.d.) 147.8 (106.2) 152.4 (108.5) 130.1 (95.7) t=1.52 NS
Median 127 132 113 U-test NS
24-h proteinuria (g/day) (stages)a
Absent (o0.30 g/day) (N (%)) 196 (68.3) 155 (66.5) 41 (75.9)g0.30–1.0 g/day (N (%)) 62 (21.6) 51 (21.8) 11 (20.4) w2=3.38 P=NS
41.0 g/day (N (%)) 29 (10.1) 27 (11.7) 2 (3.7)
Mean (s.d.) 0.93 (0.80) 0.97 (0.85) 0.66 (0.31) t=1.30 NS
Hypertension: N (%) 144 (45.3) 115 (45.6) 29 (43.9) w2=0.06 NS
P creatinine (mmol/l) (mean (s.d.)) 170.8 (213.6) 156.7 (191.9) 224.9 (276.8) t=2.33 0.02
GFR stages (N (%))
1 125 (39.3) 99 (39.3) 26 (39.4)
2 115 (36.2) 96 (38.1) 19 (28.8)
3 40 (12.6) 31 (12.3) 9 (13.6) w2=9.34 0.05
4 7 (2.2) 7 (2.8) 0 (0.0)
5 31 (9.7) 19 (7.5) 12 (18.2)
CRF (N (%)) 78 (24.5) 57 (22.6) 21 (31.8) w2=2.39 NS
Death (renal/patient) (N (%)) 33 (10.4) 21 (8.3) 12 (18.2) w2=5.45 P=0.02
Renal death (dialysis) (N (%)) 31 (9.7) 19 (7.5) 12 (18.2) w2=6.73 P=0.017
Patient death (N (%)) 2 (0.6) 2 (0.8) 0 (0.0) —
a31 patients with ESRF were excluded from this analysis (N=287); the mean proteinuria is given only for proteinuric patients.
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Figure 1 | Kaplan–Meier survival curves without renal/patient
death. End point: renal/patient death event or censored; variable:
CCR5 polymorphism.
Table 5 | Factors present at RB1 influencing survival without
ESRF by Cox monovariate analysis
Factors b/s.e. v2 P RR (95% CI)
Proteinuria/RB1 (g/day) +8.1 64.7 0.0001 1.80 (1.56–2.06)
GOS1 (unit) +8.0 64.3 0.0001 1.45 (1.33–1.59)
CRF/RB1: absence 5.4 29.2 0.0001 0.11 (0.05–0.24)
Hypertension/RB1: absence 4.3 18.1 0.0001 0.12 (0.04–0.32)
Age at onset (years) +4.2 17.8 0.0001 1.06 (1.03–1.09)
CCR5: nl/nl 3.1 9.5 0.002 0.31 (0.15–0.65)
Overweight/obesity: absence 1.9 3.5 0.06 (NS) 0.50 (0.24–1.04)
Gender: female 1.8 3.4 0.07 (NS) 0.43 (0.18–1.06)
b=regression coefficient; b/s.e.=weight of the factor (positive=deleterious; negati-
ve=protective); RR=relative risk with 95% CI.
Bold indicates the factor of interest under the present study.
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The genotype nl/nl for CCR5 was significantly protective
with RR¼ 0.57 (95% confidence interval 0.35–0.95);
P¼ 0.03. By forward stepwise multivariate Cox regression
analysis, run with all six significant covariates, CCR5
polymorphism failed to be sorted out as an independent
risk factor: nl/nl genotype: b/s.e.¼1.06; w2¼ 1.11; P¼NS.
Concerning HT, as secondary end point, the data showed
no significant differences between nl/nl and d32 genotypes in
all the analyses carried out.
DISCUSSION
In the normal Caucasian population, the genotype frequency
is about 1% for d32/d32 (homozygous) and between 10 and
15% for the heterozygous (nl/d32).6,8 The results in our
control group are totally in accordance: 1.7% for d32/d32 and
13.3% for d32/nl genotypes. The d32 allele frequency was
found to be 4.1% in a Spanish control group (N¼ 194),14
13.6% in a Danish control group (N¼ 151),15 and 3.8% in an
Italian control group (N¼ 340)16 vs 8.3% in our study, thus
indicating large variation even in Caucasian populations.
This d32 mutation has been studied in different diseases
with no significant association in asthma,17 in multiple
sclerosis,18 in myasthenia gravis,19 but controversial in
rheumatoid arthritis.15,20 More recently, a Spanish study14
was performed in systemic lupus erythematosus (N¼ 276):
overall, there was no association between CCR5 polymorph-
ism and susceptibility to this disease; however, an SLE
subgroup with biopsy-proven nephritis demonstrated a
significant increase of patients bearing ‘the d32 allele’ (20.5
vs 8.5% in SLE without nephritis; P¼ 0.03).
This CCR5 polymorphism has also been studied in renal
transplantation as a multicenter work:21 the rare homozygous
d32/d32 recipients (1.7%; N¼ 21) had significant better graft
survival vs the others (nl/nl and d32/nl). However, the
heterozygous d32/nl recipients (20.2%; N¼ 248) did not
show an intermediate phenotype, as expected.
We could find only one very recent study on CCR5
polymorphism and IGAN from Panzer U et al.,22 but the
results were completely opposite to ours. In that study, the
d32 allelic frequency was 9.0% in the 228 preselected IGAN
patients and 9.2% in the more restricted study group of 190
patients (with more demographic data), which was not so far
from our finding (11.0%). The main difference was in their
control group 12.4 vs 8.3% in ours, indicating the major
importance of local controls. Finally, in their study, the
number of IGAN patients with the d32 allele was 16.7% (38
out of 228) vs 23.5% (153 out of 651) in the controls
(w2¼ 4.64; Fisher exact test P¼ 0.003), suggesting in the
German population an influence of this polymorphism on
initiation/occurrence of IGAN (d32 allele as protective for
disease initiation/occurrence), in contrast to our findings. In
addition, both survival data gave opposite results: the curves
for survival without ESRF were diverging very late (after
about 10 years) in our study as compared to very early (first
year) in the German study; however, time zero was different:
time of biopsy in their paper vs onset of the disease for us.
We have no explanation for these major discrepancies; it
could be the variations of the disease according to different
regional populations, although these cohorts were from
Western Europe and limited to Caucasian individuals. It
could also be a bias of selection: only 10% of IGAN patients
reaching ESRF in our cohort vs 52% in the German selection
originating from 25 different centers, with 15 centers
contributing less than 10 patients!
In our study, the CCR5-32 bp deletion was associated with
major progression toward ESRF/dialysis. The role of d32
allele appeared as complex with both early protection and
late deleterious effects in d32-positive patients. Early
protection could be conferred by the absence/rarity of
crescent proliferation that is usually associated with a rapidly
progressive course towards ESRF. In our cohort, only 20
IGAN patients (20 out of 318¼ 6.3%) presented with
significant crescent proliferation (X10% of glomeruli) on
RB1, resulting in ESRF for seven patients (seven out of
20¼ 35%): one d32 patient and six nl/nl patients. By
contrast, the late deleterious effect was observed after long-
term FU and persisting even after exclusion of 20 patients
with crescent proliferation. This late effect may correspond to
the final resolution/healing phase of glomerulonephritis after
the more acute initial event(s). This would be a situation
similar to experimental data23 where blockade of CKs led
effectively to decreased glomerular leucocyte infiltration, but
overall with an aggravation/progression of the disease. In fact,
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Figure 2 | Kaplan–Meier survival curves without CRF (o60 ml/
min). End-point: CRF event or censored; variable: CCR5 poly-
morphism.
Table 6 | Influence of factors present at RB1 on survival
without CRF (o60 ml/min) by Cox monovariate analysis
Factors b/s.e. v2 P RR (95% CI)
GOS1 (units) +9.53 90.8 o0.0001 1.36 (1.27–1.45)
Age at onset (years) +8.04 64.7 o0.0001 1.07 (1.06–1.09)
Proteinuria (RB1) (g/day) +7.66 58.6 o0.0001 1.47 (1.33–1.63)
Hypertension (RB1): absence 6.82 46.5 o0.0001 0.17 (0.10–0.29)
CCR5: nl/nl 2.15 4.6 0.03 0.57 (0.35–0.95)
Overweight/obesity: absence 1.95 3.8 0.05 0.64 (0.41–1.00)
Gender: female 0.38 0.14 0.70 (NS) 0.91 (0.56–1.48)
b=regression coefficient; b/s.e.=weight of the factor (positive=deleterious; negative
=protective); RR=relative risk with 95% CI.
Bold indicates the factor of interest under the present study.
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multivariate analysis demonstrated that the normal variant
(nl/nl) was protective and associated with better outcome
and presumably less fibrosis and better healing, suggesting a
direct/indirect role for CCR5 receptor on late fibrotic lesions.
CCR5 polymorphism may also affect patient mortality with
differences between the two variants: for example, an excess of
deaths in the nl/nl patient subgroup could explain part of our
results on disease progression. In fact, CC-CK and CC-CK
receptors are playing a role in atherosclerosis. More precisely,
CCR5 and macrophage inflammatory protein 1b are present
in human arterial smooth muscle cells and in macrophages of
atherosclerotic plaques.24 In addition, individuals bearing the
d32 deletion seemed to be protected for early myocardial
infarction or severe coronary artery disease.25 In our cohort,
we have observed only two deaths before reaching ESRF.
There might be other possible explanations for our
finding. The d32 variant might be in linkage disequilibrium
with the putative gene(s) involved in IGAN progression. So,
the deleterious effect observed in our study could have been
an indirect one. On the contrary, if the d32 allele was a real
gene for progression in IGAN, we could imagine the
following sequences: IGAN is often initiated after different
acute/subacute infections; such infections would trigger the
CKs system and, more precisely, the CC-CKs; these CKs will
have decreased activity because of the CCR5 receptor
dysfunction (no function at all for rare homozygous and
decreased function for heterozygous carriers); this will
prevent from making an acute, but self-limited nephritis
with, finally, a good recovery after few months. The rare
crescentic lesions observed in IGAN might represent the
exacerbated form of such acute nephritis in IGAN; our
observation that crescentic proliferation needs to have an
intact CCR5 receptor might be an indirect argument for this
presumed mechanism. Patients with d32 allele could have a
persistent low-level infection, with inappropriate immune
response of the IGA type (IGAN background), chronic
stimulation, and finally chronic fibrotic renal lesions. In our
IGAN-STET-CO, we could not demonstrate any significant
differences in serum IGA level, between the nl/nl and the d32
groups or related to CRF or ESRF progression.
With the same prospective cohort IGAN-STET-CO, we
have performed other gene polymorphisms, including
tumour necrosis factor a26 and G protein b3 subunit27, and
none showed a significant influence on progression.
We are well aware of conflicting results concerning
association between initiation and/or progression of IGAN
on one hand, and, on the other hand, different gene
polymorphisms concerning human lymphocyte antigens or
molecules of the renin–angiotensin system (mainly insertion/
deletion for angiotensin-converting enzyme) or uteroglobin
or others. There are well-known ethnic variations in
incidence and/or prognosis of IGAN. Nevertheless, these
discrepancies often concerned the same ethnic group (for
example, Caucasian) and have been addressed for angiotensin-
converting enzyme (I, D) with finally negative data,28 but also
as a systematic review.29 The case–control study should
include large homogeneous cohorts, but the transmission
disequilibrium test should be preferred whenever possible.
There is currently a debate on genetic association with
complex diseases.30–32 In this study, we have tried to avoid the
classical pitfalls: the number of patients and controls is
obviously not small, but of medium size; our IGAN-STET-
CO included all types of prognosis without any selection; the
mean FU time was more than 10 years; the percentage of
patients lost to FU was below 10% and the percentage of
patients available for DNA analysis was 83% (318 out of 385).
Obviously, our results need to be confirmed on a larger
prospective cohort of IGAN incident cases with longer FU.
Our findings also raise the question about systematic CCR5
genotyping of patients with biopsy-proven IGAN. The cost is
limited, but will the future patients with d32 allele benefit
from closer FU and may be more aggressive treatment?
CONCLUSION
In this study, we could not demonstrate any significant role
of the d32–CCR5 polymorphism in initiation/occurrence of
primary IGAN. By contrast, the d32 allele was significantly
associated with late progression of this disease toward ESRF
with dialysis. In fact, multivariate analysis demonstrated that
the nl/nl genotype was a significant and independent
protective factor for ESRF/dialysis.
MATERIALS AND METHODS
This is a case–control study to detect significant association(s) and
compare one group of IGAN patients to a control group. Each
individual gave informed consent to this genetic study.
Prospective cohort of IGAN patients
This group included 318 consecutive patients (220 males, 69.2%)
with the diagnosis of biopsy-proven IGAN carried out in our
department during the years 1988–1999 (incident cases) with at least
1þ IgA mesangial deposits on routine immunofluorescence. We
have restricted our analysis to primary IGAN, also called Berger’s
disease, and so excluded all patients with IGAN secondary to
Scho¨nlein–Henoch purpura, liver cirrhosis, or lupus erythematosus.
In addition, we have excluded five patients with Berger’s disease
because of nonhomogenous ethnic origin (patients from North-
Africa or non-Caucasian). All these 318 patients belong to a
prospective cohort of patients recruited from the Saint-Etienne area
(IGAN-STET-CO) and regularly were followed up in our depart-
ment. This is not a natural history cohort, but this cohort includes
the whole spectrum of patients with Berger’s disease (mild, severe,
rapidly progressive courses). These patients were adequately treated/
managed for arterial HT and/or proteinuria 41 g/day and/or severe
pathological lesions if any; in fact, 55.1% (118) of patients were
receiving angiotensin-converting enzyme inhibitors and/or angio-
tensin II receptor antagonist at last FU for HT a/o proteinuria, and
86 (27%) had received high-dose steroid treatment for a few months
for severe pathological lesions.
Onset of the disease was recorded as the occurrence/discovery of
the first renal sign such as gross hematuria a/o microscopic
hematuria, a/o proteinuria a/o nephrotic syndrome and a/o CRF.
The mean (standard deviation (s.d.)) and median age at onset were,
respectively, 34.8 (15.0) and 33.4 years.
570 Kidney International (2006) 69, 565–572
o r i g i n a l a r t i c l e FC Berthoux et al.: CC-chemokine receptor five gene polymorphism
The RB1 (diagnosis) was performed at a mean time of 63.7
(94.0) and a median time of 26.8 months after onset of the disease.
At the time of diagnosis, the mean (s.d.) and median age of the
patients were, respectively, 40.6 (14.1) and 39.7 years for females,
and 39.9 (15.1) and 40.2 years for males. In all, 93 patients (29.2%)
had proteinuria greater than 1 g/day, with only 27 (8.5%) with
proteinuria over 3 g/24 h. Also, 102 patients (32.1%) were already
hypertensive (defined as blood pressure over 140/90 mmHg at two
different occasions and/or thereafter treated); 63 (19.8%) had some
degree of CRF defined as calculated creatinine clearance according
to Cockcroft–Gault formula below 60 ml/month for more than 3
months.33 Distribution of the estimated GFR indicated 42 patients
in stage 3, 13 patients in stage 4, and already eight patients in stage 5.
The mean (s.d.) and median total exposure times (from onset of
the disease to either last visit or renal/patient death) were 147.9
(106.0) months and 127.4 months (e.g. more than 10 years). At the
last FU, 144 (45.3%) were hypertensives, 78 (24.5%) had some
degree of CRF, with 31 (9.7%) in ESRF and needing dialysis (end
point). In addition, two patients died before reaching ESRF – one
male who died 81.4 months after disease onset from car accident, at
age 23.3 years, with a stage 1 GFR, and one female who died 557.7
months after disease onset from asthma/infection, at age 70.8 years,
with already a stage 4 GFR (17 ml/month). So finally, the total
number of primary events was 33 (10.4%), with 31 renal deaths and
two patient deaths.
The controls
The control group was matched for gender to fit the male
predominance in the IGAN-STET-CO.
A total of 294 healthy, local, Caucasian, unrelated volunteers
were enrolled: 206 males (70.1%) and 88 females.
Clinical and pathological data of the IGAN-STET-CO patients
Clinical data. We have collected at the time of RB1 and at last
FU the following parameters: 24 h proteinuria, plasma creatinine
(mmol/l) (with calculation of creatinine clearance (ml/min) accord-
ing to Cockcroft–Gault formula), height (m), weight (kg) with
calculation of body mass index (weight/height2¼ kg/m2). In
addition, the presence of HT and CRF was recorded.
Pathological data. The RB1 was scored according to previous
experience.34,35 We used the GOS ranging from 0 to 20, which was
the sum of glomerular (0–6), vascular (0–5), interstitial (0–5), and
tubular (0–4) indices.
Clinical progression. The primary combined end point of this
study was renal death (occurrence of ESRF with the need for dialysis;
all these patients were GFR stage 5 with a calculated creatinine
clearance below 10 ml/min at the time of first dialysis session) or
patient death occurring before ESRF/dialysis. The secondary end
points were CRF and HT.
For the purpose of comparing genotypes and alleles distribution
of CCR5 polymorphism according to the final clinical outcome, we
have stratified all these patients in three different subgroups. The
stratification was based upon staging of calculated GFR at last FU:
the subgroup with GFR stages 1 and 2 (normal) was considered as
nonprogressor, subgroup with GFR stages 3 and 4 as progressor
(towards CRF), and subgroup with GFR stage 5 as major progressor
(towards ESRF).
Genotyping of CCR5 d32 polymorphism
Genomic DNA was isolated by standard procedures from 5 ml of
venous peripheral blood drawn on EDTA.
Genotyping was performed by single polymerase chain reaction
using two specific primers. Each tube contained 250 ng of DNA
(1ml) and 20 pmol of CCR5-specific primer sense: 50-TCAAAAAG
AAGGTCTTCATTACACC-30 and of primer antisense: 50-AGCCCA
GAAGAGAAAATAAACAATC-30 in a 50-ml reaction volume. Reac-
tion conditions per cycle were the following: denaturation at 941C
for 15 s, annealing at 581C for 20 s, elongation at 721C for 30 s, and
30 cycles were run. Reaction products were separated on 3% agarose
gel (Nusieve) stained with ethidium bromide and visualized under
ultraviolet light. The normal wild allele (nl) corresponded to one
band of 241 bp and the deleted mutant (d32) allele to one band of
209 bp. So we could identify three genotypes: nl/nl with one single
241 bp band, nl/d32 with two bands: 241 and 209 bp, and d32/d32
with one single 209 bp band. All genotypes from patients and
controls with d32 allele were controlled in a separate assay and all
confirmed without exception.
Statistical analysis
Genotypes/alleles comparisons between patients and controls
and comparisons between subgroups of IGAN patients (nonpro-
gressor; progressor; major progressor). All analyses were carried
out with Statview 5.0 (Abacus Concepts Inc., Berkeley, CA, USA).
The distributions of the genotypes (nl/nl; nl/d32; d32/d32) and
alleles (nl, d32) were compared using contingency tables and
standard w2 tests.
The power of such comparison between patients and controls
was over 90%, based on the total number of alleles (individuals 2)
with a risk a¼ 0.05, a risk b¼ 0.10 and permitted a detection of a
10% difference in allelic frequencies.
Clinicopathological parameters according to different geno-
types. The quantitative (continuous) variables such as proteinuria
(g/day), body mass index and plasma creatinine were compared
with either t-test for unpaired groups or nonparametric tests such as
Mann–Whitney U-test, when applicable.
The qualitative (category) variables such as class of proteinuria,
class of body mass index, class of GFR and events like HT, CRF and
ESRF (dialysis) were compared using w2 contingency table.
Survival curves without an event. Survival curves without
renal/patient death were built with the Kaplan–Meier method and
according to the different CCR5 genotypes (nl/nl vs with d32 allele)
and compared by the log rank test: renal or patient death was the
event; time zero was the onset of the disease; the final date was either
the event occurrence date or the date of last FU for censored
patients.
All factors influencing survival data, including CCR5 genotypes,
were tested by Cox univariate analysis. In case of significant
difference(s), forward stepwise proportional hazard Cox regression
model36 (multivariate analysis) was used with all significant
covariates and at least the already known independent risk factors
for progression,35 such as age at onset,13 arterial HT, GOS, 24-h
proteinuria and body mass index.37
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Appendix
Validity of the previous results with compliance to the
Hardy–Weinberg equilibrium
The numbers of observed genotypes were not significantly
different (w2 test) from the theoretical numbers calcu-
lated, from the Hardy–Weinberg formula, using the allelic
frequencies.
For IGAN-STET-CO, nl allele¼ 0.890; d32 allele¼ 0.110;
nl/nl genotype¼ 0.8902 318¼ 252; d32/d32 genotype¼
0.1102 318¼ 4; nl/d32 genotype¼ 2 (0.890 0.110)
318¼ 62.
For controls: nl allele¼ 0.917; d32 allele¼ 0.083; nl/nl
genotype¼ 0.9172 294¼ 247; d32/d32 genotype¼ 0.0832
294¼ 2; nl/d32 genotype¼ 2 (0.917 0.083) 294¼ 45 as
compared, respectively, to 250, 5 and 39 (w2¼ 1.73; P¼NS).
For patients subgroups:
K Nonprogressors: nl allele¼ 0.902; d32 allele¼ 0.098; nl/nl
genotype¼ 0.9022 240¼ 195; d32/d32 genotype¼
0.0982 240¼ 2; nl/d32 genotype¼ 2 (0.902 0.098)
240¼ 42.
K Progressors: nl allele¼ 0.904; d32 allele¼ 0.096; nl/nl
genotype¼ 0.9042 47¼ 38; d32/d32 genotype¼ 0.0962
47¼ 0 (0.4); nl/d32 genotype¼ 2 (0.904 0.096)
47¼ 8.
K Major progressors: nl allele¼ 0.774; d32 allele¼ 0.226;
nl/nl genotype¼ 0.7742 31¼ 19; d32/d32 genotype¼
0.2262 31¼ 2; nl/d32 genotype¼ 2 (0.774 0.226)
31¼ 11.
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